

**LUD 5466.4 CIP - JEL/NDH**

- Claim 89: An isolated polypeptide which binds to an MHC-Class II DR53 molecules, wherein said polypeptide has an amino acid set forth in SEQ ID NO: 8, 9, 10, 11, 12 or 13.
- Claim 90: The isolated polypeptide of claim 89, the amino acid sequence of which is set forth at SEQ ID NO: 8, 9 or 10.
- Claim 91: A composition comprising the isolated polypeptide of claim 89, and at least one adjuvant.
- Claim 92: The composition of claim 91, wherein said polypeptide has the amino acid sequence set forth in SEQ ID NO: 8, 9 or 10.
- Claim 93: A composition comprising a mixture of at least two of the polypeptides defined by SEQ ID NOS: 8, 9 and 10.
- Claim 94: The composition of claim 93, further comprising an adjuvant.
- Claim 95: A composition comprising:
- (i) a first polypeptide, the amino acid sequence of which consists of the amino acid sequence set forth in SEQ ID NO: 7, and
  - (ii) at least one additional polypeptide, the amino acid sequence of which consists of the amino acid sequence set forth in SEQ ID NO: 8, 9 or 10.

**REMARKS**

Entry of the amendment is requested.

Claims 89-95 replace claims 76, 77, 79-81 and 86. Claims 84 and 88-95 will be pending.

Claims 84 and 88 have been allowed. Claims 76, 77, 79-81 and 86 were objected to as depending from rejected claims. They no longer do, and should be deemed allowable.

These changes are presented to advance prosecution, and not out of agreement with the examiner. Applicants reserve their rights to file additional divisionals and continuations to subject matter not pursued here.

With respect to the remarks regarding the oath, the examiner is reminded that the statutes and regulations are very clear that such issues are resolvable following allowance.